medicina58巻3号

2021年03月発行

特集 いまさら聞けない！ 肝胆膵疾患—みなさんのギモンに答えます 日常遭遇する肝障害

脂肪肝の合併症と経過観察・治療

著者： 川口巧¹ 鳥村拓司¹

所属機関： ¹久留米大学医学部内科学講座消化器内科部門

ページ範囲：P.428 - P.431

Question 1
脂肪肝をみたら，どんな合併症を調べるべきですか？

参考文献

1）日本消化器病学会，日本肝臓学会（編）：NAFLD/NASH診療ガイドライン2020（改訂第2版）．南江堂，2020

2）Mantovani A, et al：Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S：154170, 2020

3）Kawaguchi T, Torimura T：Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients? J Gastroenterol 55：363-364, 2020

4）Kim GA, et al：Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol S0168-8278：32294-32298, 2017

5）Nakahara T, et al：Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 49：1477-1484, 2014

6）Sertoglu E, et al：The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem 47：383-388, 2014

7）Eslam M, et al：A new definition for metabolic dysfunction-associated fatty liver disease；An international expert consensus statement. J Hepatol 73：202-209, 2020

8）Yamamura S, et al：MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int, 2020［Online ahead of print］

9）Mahady SE, et al：The role of thiazolidinediones in non-alcoholic steatohepatitis；A systematic review and meta analysis. J Hepatol 55：1383-1390, 2011

10）Musso G, et al：Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis；A meta-analysis. JAMA Intern Med 177：633-640, 2017

11）Armstrong MJ, et al：Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis（LEAN）；A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387：679-690, 2016

12）Yan J, et al：Liraglutide, sitagliptin, and insulin glargine added to metformin；The effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology 69：2414-2426, 2019

13）Kuchay MS, et al：Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease；A randomized controlled trial（E-LIFT Trial）. Diabetes Care 41：1801-1808, 2018

14）Ito D, et al：Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes；A randomized, 24-week, open-Label, active-controlled trial. Diabetes Care 40：1364-1372, 2017

15）Tang H, et al：SGLT2 inhibitors and risk of cancer in type 2 diabetes；A systematic review and meta-analysis of randomised controlled trials. Diabetologia 60：1862-1872, 2017

16）Kawaguchi T, et al：Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis-related cytokines after treatment with sodium-glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus. Hepatol Res 49：479-486, 2019

17）Kaji K, et al：Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 142：1712-1722, 2018

18）Nakano D, et al：Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells；Multi-omics analysis of metabolomics and absolute quantification proteomics（iMPAQT）. PLoS One 15：e0232283, 2020

19）Eslami L, et al：Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev：CD008623, 2013

20）Alam S, et al：Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis；A 1-year randomized control trial. Saudi J Gastroenterol 22：69-76, 2016

21）Goh GB, et al：Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 35：979-985, 2015

22）Sato K, et al：Vitamin E has a beneficial effect on nonalcoholic fatty liver disease；A meta-analysis of randomized controlled trials. Nutrition 31：923-930, 2015

23）Lonn E, et al：Effects of long-term vitamin E supplementation on cardiovascular events and cancer；A randomized controlled trial. JAMA 293：1338-1347, 2005